The Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI; MPS VI) is a lysosomal storage disease caused by deficiency of the enzyme arylsulphatase B (ASB). A human ASB cDNA has been subcloned into the retroviral vector pXTl containing the bacterial neomycin-resistance gene and an internal thymidine kinase promoter for transcription of the inserted gene. Replication defective retrovirus was generated by transfecting the construct into the amphotropic packaging cell line PA3 17. Human MPS VI fibroblasts infected with recombinant retrovirus integrated the provirus into their genome and expressed retrovirus-encoded ASB mRNAs. In infected fibroblasts the level of ASB was up to 36-fold higher than in normal fibroblasts. Biosynthesis and processing of ASB in infected MPS VI fibroblasts was accomplished as in normal fibroblasts, and mature, enzymically active, ASB accumulated in dense lysosomes, indicating that the ASB deficiency in MPS VI fibroblasts was corrected by the retroviral gene transfer.
INTRODUCTION
Mucopolysaccharidosis type VI (MPS VI) is a glycosaminoglycan storage disorder with autosomal recessive inheritance resulting from a deficiency of the lysosomal enzyme arylsulphatase B (ASB; EC 3.1.6.1). ASB catalyses the hydrolysis of the sulphate ester group from N-acetylgalactosamine 4-sulphate residues of dermatan sulphate (Matalon et al., 1974; O'Brien et al., 1974) . Deficiency of ASB activity leads to intralysosomal accumulation and urinary excretion of partially degraded dermatan sulphate. MPS VI patients exhibit a variety of clinical phenotypes. Patients with the severe form of the disease present corneal clouding, hepatosplenomegaly, skeletal malformation and growth retardation, whereas the mental development is normal or near-normal in all MPS VI forms. Most patients with severe MPS VI die of heart failure in the second or third decade [for a review, see Neufeld & Muenzer (1989) ].
Currently there is no specific treatment of mucopolysaccharidoses available. Attempts to replace the deficient lysosomal enzymes by infusion of purified enzyme, plasma or leucocytes yielded, if at all, only transient improvement. The limited amount of enzymes infused and the lack of functional recognition markers necessary for receptor-mediated endocytosis of the infused lysosomal enzymes may -explain the disappointing results of these therapeutic trials. As an alternative approach allogenic bone--marrow transplantation was pursued in several mucopolysaccharidoses under the assumption that haematopoetic progenitor cells (e.g. tissue macrophages) will secrete lysosomal enzymes, which can be taken up by the host cells and restore the deficient enzyme activity. A bone-marrow transplantation in a patient with severe MPS VI resulted in an increase of ASB activity in peripheral lymphocytes and granulocytes, a decrease in urinary glycosaminoglycan excretion and substantial reduction of the hepatosplenomegaly, but no improvement of visual and skeletal involvement was achieved (Krivit et al., 1984) . Allo- genic bone-marrow transplantation, even when HLA (histocompatibility antigens)-identical donors are available, carries a high risk of mortality and morbidity from graft-versus-host disease (Neufeld & Muenzer, 1989) .
With the development of replication-defective retroviral vectors capable of efficient transfer and expression of genes in a variety of mammalian cells, approaches to somatic-cell gene therapy for certain genetic disorders has become feasible (Anderson, 1984; Keller et al., 1985; Temin, 1986) . Hitherto these approaches have focused on gene transfer into haematopoetic stem cells in vitro and subsequent implantation of the manipulated cells into recipient animals. In contrast with the murine system, where stable levels of expression in cells derived from the haematopoetic system in vivo have been reported (Eglitis et al., 1985; Keller et al., 1985; Dzierzak et al., 1987) , this approach has been seriously hampered in dogs and monkeys, owing to poor infection of haematopoetic stem cells in vitro and rapidly declining expression in vivo (Williams et al., 1986; Kantoff et al., 1987; Mclvor et al., 1987; Stead et al., 1988) . Skin fibroblasts provide an alternative target for gene therapy, since they can be efficiently infected with retroviruses and subsequently selected and expanded in culture (Palmer et al., 1987; Miyanohara et al., 1988; Osborne & Miller, 1988) . Furthermore, it has been shown that retrovirus-infected mouse fibroblasts that expressed a foreign gene coding for a secretory protein in vitro continued to express stable amounts of this gene product in vivo even in the absence of selective pressure (Garver et al., 1987) .
MPS VI appears to be an appropriate model for gene therapy approaches of lysosomal storage diseases, since ASB cDNAs have been isolated recently (Peters et al., 1990; Schuchman et al., 1990) . Furthermore, a feline model of the disease has been described (Jezyk et al., 1977) , and a successful allogenic bonemarrow transplantation in an affected cat resulting in encouraging improvements of the symptoms has been reported (Gasper et al., 1984 
Production of recombinant retrovirus XT-ASB
The 1903 bp XhoI-Sall DNA fragment of plasmid pCA7 encoding the first 29 amino acids of the signal peptide of lysosomal acid phosphatase and amino acids 37-533 of ASB (Peters et al., 1990 ) was ligated into the XhoI site of the retroviral expression vector pXTl (Boulter & Wagner, 1987) . The orientation of the insert in the resulting plasmid pXT-ASB was checked by digestion with the restriction enzymes SstI and XhoI + Sall; plasmid pXT-ASB was amplified in Escherichia coli strain HB1O1 in the presence of ampicillin (200 jug/ml). Replication-defective infectious retrovirus particles were generated by transfection of plasmid pXT-ASB into the helpervirus free-packaging cell line PA317 (Miller & Buttimore, 1986) using the calcium phosphate technique (Wigler et al., 1977) . At 72 h after transfection, G418 (geneticin; Gibco; 0.4 mg/ml) was added to the culture medium. Resistant cells were treated with trypsin, subcloned and recultured to approx. 500% confluency. Selection was withdrawn for 2 days and the culture medium was filtered through a 0.45 jm-pore-size filter.
Retroviral gene transfer
At 48 h before infection, human MPS VI fibroblasts were seeded at 30 % confluency into a 75 mm2 culture flask. Cells were incubated in 2 ml of the filtered culture supernatant of XT-ASBproducing PA317 cells for 16 h in the presence of Polybrene (10 jg/ml). At 48 h after infection, culture medium was supplemented with G418 (0.2 mg/ml), and fibroblasts were selected in comparison with an uninfected control. G418-resistant MPS VI fibroblasts were assayed for ASB activity, and expressing cells were used for further investigations.
Enzyme assays
In cell extracts, ASB activity was measured after immunoprecipitation of ASB with an ASB-specific antiserum ) using p-nitrocatechol sulphate as substrate. A unit of activity is the amount of enzyme catalysing the formation of Iumol of p-nitrocatechol/min. Protein was determined by Bio-Rad protein assay (500-0006), with BSA as standard. ,J-Hexosaminidase activity was determined as described by von Figura (1977) .
DNA preparation and Southern-blot analysis
Genomic DNA was isolated from human fibroblast lines essentially as described by Sambrook et al. (1989) , digested with restriction endonucleases, separated by electrophoresis through a 0.6 %-agarose gel and transferred to Hybond-N membranes (Amersham Corp.; Southern, 1975 Lemansky et al. (1985) . For the chase, the medium was supplemented with 1 % of a 20 mg/ml solution of methionine. The cells were harvested by scraping, and cell extracts were prepared as described by Lemansky et al. (1985) . Postnuclear supernatants obtained from metabolically labelled cells (on confluent 60 mm-diameter dishes) were fractionated by Percolldensity-gradient centrifugation as described by Waheed et al. (1988) .
Immunoprecipitation and electrophoresis
The extract of cells, the medium and Percoll-density-gradient fractions were immunoprecipitated using an anti-ASB antiserum and analysed by SDS/PAGE as described by Waheed et al. (1988) .
Indirect immunofluorescence
Cells were grown on coverslips, fixed and permeabilized as described by Waheed et al. (1988) . After permeabilization, cells were incubated for 1.5 h with an anti-ASB antiserum , followed by an incubation with tetramethylrhodamine-conjugated anti-rabbit IgG (Cappel) for 1 h.
RESULTS
A retroviral vector, XT-ASB (Fig. 1) A 10 jug portion of the respective genomic DNA was digested with EcoRI (E) or XbaI (X) and probed with a human ASB cDNA. The 6.3 kb XbaI and 2.0 kb EcoRI fragments detected in retrovirusinfected MPS VI fibroblasts (3) correspond to the expected lengths of intact ASB-cDNA-containing provirus (see Fig. 1 ). The 6.1 kb XbaI fragment (3) is most likely due to a short deletion in a subpopulation of the provirus.
peptide of human lysosomal acid phosphatase and amino acids 37-533 of human ASB, which previously has been shown to code for active ASB (Peters et al., 1990) , was inserted into the plasmid form of the retroviral expression vector pXTI (Boulter & Wagner, 1987) . pXTl is an N2-based retroviral vector (Keller et al., 1985) providing an internal herpes-simplexvirus thymidine kinase (TK) promoter (Colbere-Garapin et al., 1979; McKnight & Kingsbury, 1982) for G418 resistance resulted in normal or elevated levels of ASB activity (Table 1) . Southern-blot analysis of genomic DNA was from MPS VI cell line 5343,C5, expressing large amounts of ASB after retroviral-gene transfer (Table 1) , revealed, in addition to the pattern of DNA restriction fragments observed in the uninfected parental MPS VI fibroblast line 5343 and a normal fibroblast line, an EcoRI DNA fragment of 2.0 kb and an XbaI fragment of 6.3 kb hybridizing with the ASB cDNA probe (Fig.  2) . These two fragments were expected for the correctly integrated retroviral vector XT-ASB (Fig. 1 ). An additional XbaI fragment of about 6.1 kb in 5343,C5 DNA is possibly due to a small deletion in a subpopulation of the integrated provirus (Fig. 2) . Three transcripts from XT-ASB of expected size were detected by Northern-blot analysis of RNA from 5343,C5 fibroblasts. These transcripts are not present in the uninfected parental fibroblast line 5343 (Fig. 3) . A genomic RNA of approx. 6.3 kb and a subgenomic transcript of 5.8 kb are presumably initiated at the 5'LTR of XT-ASB, whereas a 3.0 kb transcript is initiated at Fig. 6 . Immunofluorescence of ASB in retrovirus-infected MPS VI fibroblasts MPS VI fibroblasts (a) and retrovirus XT-ASB infected MPS VI fibroblasts (b) were incubated with rabbit anti ASB antiserum, followed by tetramethylrhodamine-conjugated anti-rabbit IgG.
the internal TK promoter. On longer exposure, the endogenous transcripts of the ASB gene, 4.8, 2.5 and 1.8 kb in size (see Fig.  3 of Peters et al., 1990) , are visible in the RNA of uninfected 5343 fibroblasts (results not shown).
To investigate the synthesis and processing of ASB expressed in MPS VI fibroblasts after retroviral-gene transfer, 5343,C5 fibroblasts were metabolically labelled for 2 h with [35S]methionine and chased for up to 16 h. After a 2 h pulse a 64 kDa polypeptide, considered to represent the ASB precursor, was immunoprecipitated from the cell extract (Fig. 4, lane 1) . A polypeptide of the same size was -detectable in the secretions when the cells were labelled and chased in the presence of 10 mmNH4Cl (Fig. 4, lane 6 ). NH4Cl is known to induce secretion of precursors of lysosomal enzymes (Hasilik & Neufeld, -1980; Myerowitz & Neufeld, 1981) including those of ASB Peters et al., 1990; Taylor et al., 1990) . During a 16 h chase the 64 kDa precursor disappeared and a 47 kDa and a 12.5 kDa polypeptide accumulated in the cell extract (Fig. 4, lane  2) . Localization of ASB in MPS VI fibroblasts after retroviralgene transfer was demonstrated in two experiments. Subcellular fractionation of 5343,C5 fibroblasts by Percoll-density-gradient centrifugation revealed that approx. 600% of ASB activity was associated with the dense lysosomes, paralleling the distribution of ,/-hexosaminidase, a lysosomal marker (Fig. Sb, II) . A similar distribution has previously been shown for ASB expressed in BHK-21 cells (Peters et al., 1990) . Immunoprecipitation from the gradient fractions showed that the mature 47 kDa ASB form predominantly fractionated with the dense lysosomes (Fig. 5a , II, lane 1). A small part of the 47 kDa polypeptide fractionates with the light membranes (Fig. 5a , II, lanes 5 and 6).
Furthermore, ASB was detected by indirect immunofluorescence in 5343,C5 fibroblasts, exhibiting granular distribution predominantly in the perinuclear area (Fig. 6b) , typical for lysosomal distribution (Parenti et al., 1987) . The intensities of ASB-specific signals varied between individual cells, suggesting large differences in expression ofASB activity (results not shown). No ASB-cross-reacting material was detected in the uninfected MPS VI cell line 5343 (Fig. 6a) . 
DISCUSSION
The results described here demonstrate that a human ASB cDNA inserted into a retroviral vector can be efficiently transferred in vitro into human fibroblasts of a patient suffering from the Maroteaux-Lamy syndrome. After infection with the recombinant retrovirus, ASB enzyme activity rose from undetectable levels before gene transfer to up to 36-fold overexpression, as compared with normal fibroblasts. The retrovirus-encoded ASB polypeptides were shown to be synthesized and processed as endogenous ASB in normal fibroblasts (Taylor et al., 1990) and human ASB expressed in baby-hamster-kidney cells (BHK-21; Peters et al.., 1990 ); a 64 kDa precursor was processed to the mature form of the enzyme, which is composed of two polypeptides of 47 kDa and 12.5 kDa in. size. Appearance.of the mature form of ASB suggests that the ASB precursor is transported to the lysosomal compartment, where proteolytic processing is accomplished. Localization of retrovirus-encoded ASB in dense lysosomes was furthermore demonstrated by Percoll-density-gradient centrifugation and indirect immunofluorescence.
Correction of enzyme deficiency in vitro by retroviral-gene transfer has recently been reported for two other lysosomal storage diseases. Human glucocerebrosidase has been expressed in fibroblasts (Choudary et al., 1986; Sorge et al., 1987) and haematopoetic cells (Fink et al., 1990) from Gaucher patients. A rat /J-glucuronidase cDNA has been introduced into human fibroblasts of patients with mucopolysaccharidosis type VII, as well as into fibroblasts, retinal epithelia cells and haematopoetic cells of a fl-glucuronidase-deficient dog (Wolfe et al., 1990) .
Histochemical staining revealed that only a subpopulation of the treated cells contained ,-glucuronidase activity, paralleling our observation of large differences in ASB-specific staining between individual cells in indirect immunofluorescence.
The retroviral vector construct XT-ASB described here may be used for transfer of the ASB cDNA into haematopoetic cells of the feline MPS VI model. Subsequent autologous bonemarrow transplantation could help to evaluate the prospects of somatic gene therapy of Maroteaux-Lamy disease in humans. However, efficient infection of uncommitted haematopoetic stem cells and maintenance of high levels of expression of the transferred gene over long periods of time represent major obstacles recently encountered in gene-transfer experiments in dogs and monkeys (Kantoff et al., 1987; Stead et al., 1988) .
Skin fibroblasts may be an attractive alternative tissue for gene-therapy approaches to lysosomal storage diseases (Osborne & Miller, 1988; Friedmann, 1989) . In the feline MPS VI model, fibroblasts reimplanted into the animal after correction of the ASB.deficiency in vitro could serve as a source of the enzyme. To increase the amount of enzyme secreted into the circulation, the gene for the Mr-46000 mannose 6-phosphate receptor could be transferred into the fibroblasts along with the ASB cDNA (Chao et al., 1990) and thereby extend the supply of ASB available for endocytosis into affected cells.
